Pharma: Be Prepared For Tougher Price Negotiations For IO Combos And Expansions In Europe
Executive Summary
Payers are increasingly likely to implement new strategies to manage price negotiations for immuno-oncology combinations, as competition heats up among the drug class. Mechanisms allowing for the negotiation of different prices for combination therapies do not exist at present, but payers insist that new tools must emerge.
You may also be interested in...
BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451
BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.
Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant disease.
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.